Introduction: GBS is a rare condition in children. The risk factors for GBS are present in Africa; however, the majority of studies reported are case series. The objective of our work was to evaluate the epidemiological, clinical, paraclinical, therapeutic and evolutionary profile of GBS cases. Material and Method: This was a prospective longitudinal study, lasting 24 months between November 2019 and November 2021. All patients aged 2 - 18 years diagnosed with GBS according to the Brighton criteria (level 2) were included in our study. Patients with incomplete or unexploitable records were excluded. Results: Over a 24-month period, 16 cases of GBS were collected. These included 12 boys (75%) and 4 girls (25%). The demyelinating form (ADIP) was found in 9 children (43.75%) and the axonal form in 7 patients (37.5%), 5 of whom had pure motor involvement (AMAN) and 2 with sensory-motor involvement (AMSAN). Corticosteroid therapy was more effective in treating pain and in demyelinating forms. Three deaths were noted and all had AMAN. Conclusion: GBS poses a management problem in our context of a country with limited resources. Corticosteroid therapy has been shown to be effective in the treatment of pain and demyelinating forms of the disease and should be considered for use in GBS.
References
[1]
Asbury, A.K. (2000) New Concepts of Guillain-Barré Syndrome. Journal of Child Neurology, 15, 183-191. https://doi.org/10.1177/088307380001500308
[2]
Asbury, A.K. and Cornblath, D.R. (1990) Assessment of Current Diagnostic Criteria for Guillain-Barré Syndrome. Annals of Neurology, 27, S21-S24. https://doi.org/10.1002/ana.410270707
[3]
Hafsteinsdóttir, B., ólafsson, E. and Jakobsson, F. (2018) Incidence and Outcome of Guillain-Barré Syndrome in Iceland: A Population-Based Study. Acta Neurologica Scandinavica, 138, 454-458. https://doi.org/10.1111/ane.13000
[4]
Levison, L.S., Thomsen, R.W., Markvardsen, L.K., et al. (2009) Pediatric Guillain-Barré Syndrome in a 30-Year Nationwide Cohort. Pediatric Neurology, 107, 57-63. https://doi.org/10.1016/j.pediatrneurol.2020.01.017
[5]
McGrogan, A., Madle, G.C., Seaman, H.E., et al. (2009) The Epidemiology of Guillain-Barré Syndrome Worldwide. Neuroepidemiology, 32, 150-163. https://doi.org/10.1159/000184748
[6]
Willison, J., Van Doorn, H.J. and Bart, P. (2016) Guillain-Barré Syndrome. The Lancet, 388, 717-727. https://doi.org/10.1016/S0140-6736(16)00339-1
[7]
Akolly, D., et al. (2016) Syndrome De Guillain-Barré Chez L’enfant Dans Un Contexte A Ressources Limitées: A Propos De Deux Observations Au CHU Sylvanus Olympio De Lomé—TOGO. European Scientific Journal, 12, 182-188. https://doi.org/10.19044/esj.2016.v12n36p182
[8]
Hughes, R.A. (2004) Treatment of Guillain-Barré Syndrome with Corticosteroids: Lack of Benefit? The Lancet, 363, 181-182. https://doi.org/10.1016/S0140-6736(03)15367-6
[9]
Mastaglia, F.L. (2005) Neuromuscular Disorders: Molecular and Therapeutic Insights. The Lancet Neurology, 4, 6-7. https://doi.org/10.1016/S1474-4422(04)00946-9
[10]
Nagasawa, K., Kuwabara, S., Misawa, S., et al. (2006) Electrophysiological Subtypes and Prognosis of Childhood Guillain-Barré Syndrome in Japan. Muscle & Nerve, 33, 766-770. https://doi.org/10.1002/mus.20520
[11]
Jacobs, B.C., van Doorn, P.A., Schmitz, P.I., Tio-Gillen, A.P., Herbrink, P., Visser, L.H., et al. (1996) Campylobacter jejuni et anticorps anti-GM1 dans le syndrome de Guillain-Barré. Annals of Neurology, 40, 181-187. https://doi.org/10.1002/ana.410400209
[12]
Sharshar, T., Siami, S. and Orlikowski, D. (2007) Does This Patient Have Guillain-Barré Syndrome? Resuscitation, 16, 504-510. https://doi.org/10.1016/j.reaurg.2007.09.006
[13]
Bradshaw, D.Y. and Jones, H.R. (1992) Guillain-Barré Syndrome in Children: Clinical Course, Electrodiagnosis, and Prognosis. Muscle & Nerve, 15, 500-506. https://doi.org/10.1002/mus.880150415
[14]
Goodfellow, J.A. and Willison, H.J. (2016) Guillain-Barré Syndrome: A Century of Progress. Nature Reviews Neurology, 12, 723-731. https://doi.org/10.1038/nrneurol.2016.172
[15]
Webb, A.J.S., Brain, S.A.E., Wood, R., et al. (2015) Seasonal Variation in Guillain-Barré Syndrome: A Systematic Review, Meta-Analysis and Oxfordshire Cohort Study. Journal of Neurology, Neurosurgery and Psychiatry, 86, 1196-1201. https://doi.org/10.1136/jnnp-2014-309056
[16]
Kuwabara, S. and Yuki, N. (2013) Axonal Guillain-Barré Syndrome: Concepts and Controversies. The Lancet Neurology, 12, 1180-1188. https://doi.org/10.1016/S1474-4422(13)70215-1
[17]
Wu, X., Li, C., Zhang, B., et al. (2015) Predictors for Mechanical Ventilation and Short-Term Prognosis in Patients with Guillain-Barré Syndrome. Critical Care, 19, Article No. 310. https://doi.org/10.1186/s13054-015-1037-z
[18]
Devos, D., Magot, A., Perrier-Boeswillwald, J., et al. (2013) Guillain-Barré Syndrome during Childhood: Particular Clinical and Electrophysiological Features: GBS in Childhood. Muscle & Nerve, 48, 247-251. https://doi.org/10.1002/mus.23749
[19]
Hughes, R.A., Brassington, R., Gunn, A.A. and van Doorn, P.A. (2016) Corticosteroids for Guillain-Barré Syndrome. Cochrane Database of Systematic Reviews, 10, CD001446. https://doi.org/10.1002/14651858.CD001446.pub5
[20]
Ma, L.Z., Liu, S.P., Xiao, Z.M., et al. (2022) Comparison of the Effects of Different Doses of Glucocorticoids on Distinct Subtypes of Guillain-Barré Syndrome in South China. BMC Neurology, 22, Article No. 46. https://doi.org/10.1186/s12883-022-02567-8
[21]
Kabore, R., Magy, L., Boukhris, S., et al. (2004) The Value of Corticosteroid Therapy in the Treatment of Pain in the Acute Phase of Guillain-Barré Syndrome. Revue Neurologique (Paris), 160, 821-823. https://doi.org/10.1016/S0035-3787(04)71037-1
